10x Genomics Inc. reported preliminary, unaudited select financial results for the fourth quarter (Q4) and full year ended December 31, 2025. Revenue for Q4 2025 was approximately USD 166.0 million, reflecting an 11 percent sequential increase and a 1 percent rise compared to the corresponding prior-year period. Single Cell consumables reactions sold increased by more than 20 percent compared to the prior year period. As of December 31, 2025, cash, cash equivalents, and marketable securities totaled approximately USD 520 million. These results are preliminary and subject to adjustment as the company completes its year-end financial close and review procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60601) on January 11, 2026, and is solely responsible for the information contained therein.